Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Excessive iron absorption is one of the main features of β-thalassemia and can lead to severe morbidity and mortality. Serial analyses of β-thalassemic mice indicate that while hemoglobin levels decrease over time, the concentration of iron in the liver, spleen, and kidneys markedly increases. Iron overload is associated with low levels of hepcidin, a peptide that regulates iron metabolism by triggering degradation of ferroportin, an iron-transport protein localized on absorptive enterocytes as well as hepatocytes and macrophages. Patients with β-thalassemia also have low hepcidin levels. These observations led us to hypothesize that more iron is absorbed in β-thalassemia than is required for erythropoiesis and that increasing the concentration of hepcidin in the body of such patients might be therapeutic, limiting iron overload. Here we demonstrate that a moderate increase in expression of hepcidin in β-thalassemic mice limits iron overload, decreases formation of insoluble membrane-bound globins and reactive oxygen species, and improves anemia. Mice with increased hepcidin expression also demonstrated an increase in the lifespan of their red cells, reversal of ineffective erythropoiesis and splenomegaly, and an increase in total hemoglobin levels. These data led us to suggest that therapeutics that could increase hepcidin levels or act as hepcidin agonists might help treat the abnormal iron absorption in individuals with β-thalassemia and related disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since hepcidin arises as a key iron-regulated gene due to its function as a sensor for systemic iron availability, several strategies are envisioned to manipulate its expression [81].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [81]
In the citing paper
“Thus, transgenic expression of hepcidin prevented iron overload in Hfe−∕− (Nicolas et al., 2003) and Hbbth3∕+ (Gardenghi et al., 2010) mice, models of HH and β-thalassemia intermedia, respectively.”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Gardenghi et al., 2010
In the citing paper
“Moreover, manipulation of hepcidin levels by these strategies also improved erythropoiesis in Hbbth3∕+ mice (Gardenghi et al., 2010; Nai et al., 2012).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Gardenghi et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Self-citationHepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168 · cited 3×
“Similarly, low HAMP levels have been measured in the urine of patients with β-thalassemia (15), further supporting this hypothesis.”
BackgroundPigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697 · cited 1×
“In the latter group of mice, egress of iron from macrophages was not expected to be altered since Hamp1 is extremely low under conditions of iron deficiency (17).”
BackgroundLEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity
Krause, A., Neitz, S., Mägert, H.-J., Schulz, A., Forssmann, W.-G., Schulz-Knappe, P., & Adermann, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01920-7 · Cited by 1,324 · cited 3×
“Similarly, low HAMP levels have been measured in the urine of patients with β-thalassemia (15), further supporting this hypothesis.”
BackgroundChen, K., Liu, J., Heck, S., Chasis, J. A., An, X., & Mohandas, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909296106 · Cited by 524 · cited 14×
“This assay allows the separation of erythroid cells into distinct populations corresponding to proerythroblasts (fraction I), basophilic (II), polychromatic (III), orthochromatic cells, and reticulocytes (IV), and mature rbc (V) (Supplemental Figure 6, only spleen is shown; similar results were observed in the BM) (18…”
MethodResultInfluentialSelf-citationMcEwen, E., Kedersha, N., Song, B., Scheuner, D., Gilks, N., Han, A., Chen, J.-J., Anderson, P., & Kaufman, R. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412882200 · Cited by 447 · cited 1×
“Previously presented data demonstrate that the absence of heme-regulated inhibitor (HRI) kinase, which controls Hb synthesis (25), exacerbates the β-thalassemia phenotype (26), while lack of heme exporter feline leukemia virus subgroup C cellular receptor (FLVCR), which controls heme export (27), impairs rbc formation…”
BackgroundHepcidin in iron overload disorders
Papanikolaou, G., Tzilianos, M., Christakis, J. I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y. P., Sakellaropoulos, N., Ganz, T., & Nemeth, E. (2005) · Blood · doi:10.1182/blood-2004-12-4844 · Cited by 445 · cited 1×
“Similarly, low HAMP levels have been measured in the urine of patients with β-thalassemia (15), further supporting this hypothesis.”
BackgroundSelf-citationDisorders of hemoglobin genetics, pathophysiology, and clinical management
Steinberg, M. H. (2001) · Cited by 438
Identification of a Human Heme Exporter that Is Essential for Erythropoiesis
Quigley, J. G., Yang, Z., Worthington, M. T., Phillips, J. D., Sabo, K. M., Sabath, D. E., Berg, C. L., Sassa, S., Wood, B. L., & Abkowitz, J. L. (2004) · Cell · doi:10.1016/j.cell.2004.08.014 · Cited by 430 · cited 1×
“Previously presented data demonstrate that the absence of heme-regulated inhibitor (HRI) kinase, which controls Hb synthesis (25), exacerbates the β-thalassemia phenotype (26), while lack of heme exporter feline leukemia virus subgroup C cellular receptor (FLVCR), which controls heme export (27), impairs rbc formation…”
BackgroundSurvival and Complications in Thalassemia
BORGNA‐PIGNATTI, C., CAPPELLINI, M. D., DE STEFANO, P., DEL VECCHIO, G. C., FORNI, G. L., GAMBERINI, M. R., GHILARDI, R., ORIGA, R., PIGA, A., ROMEO, M. A., et al. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.006 · Cited by 426 · cited 1×
“NTBI serves as a catalyst for the formation of ROS, which can cause myocyte damage, arrhythmias, and congestive heart failure, the main causes of death in patients with β-thalassemia (22).”
Background
Cited by
A Red carpet for iron metabolism
Muckenthaler, M. U., Rivella, S., Hentze, M. W., & Galy, B. (2017) · Cell · doi:10.1016/j.cell.2016.12.034 · Cited by 1,319
Self-citationGanz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Self-citationGanz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
“Unexpectedly, iron overload in mouse models of -thalassemia has a deleterious effect on erythropoiesis that can be reversed by interventions that increase hepcidin production (85, 159).”
BackgroundIdentification of erythroferrone as an erythroid regulator of iron metabolism
Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127
Self-citationHepcidin and iron regulation, 10 years later
Ganz, T. (2011) · Blood · doi:10.1182/blood-2011-01-258467 · Cited by 962
Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31822-6 · Cited by 807
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Hepcidin and the iron-infection axis
Drakesmith, H., & Prentice, A. M. (2012) · Science · doi:10.1126/science.1224577 · Cited by 686
Iron Overload in Human Disease
Fleming, R. E., & Ponka, P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1004967 · Cited by 587
Iron overload in thalassemia: different organs at different rates
Taher, A. T., & Saliba, A. N. (2017) · Hematology · doi:10.1182/asheducation-2017.1.265 · Cited by 355
Non-transfusion-dependent thalassemias
Musallam, K. M., Rivella, S., Vichinsky, E., & Rachmilewitz, E. A. (2013) · Haematologica · doi:10.3324/haematol.2012.066845 · Cited by 326
Self-citationKattamis, A., Kwiatkowski, J. L., & Aydinok, Y. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00536-0 · Cited by 313
Kautz, L., Jung, G., Du, X., Gabayan, V., Chapman, J., Nasoff, M., Nemeth, E., & Ganz, T. (2015) · Blood · doi:10.1182/blood-2015-07-658419 · Cited by 306
Self-citationAnemia: progress in molecular mechanisms and therapies
Sankaran, V. G., & Weiss, M. J. (2015) · Nature Medicine · doi:10.1038/nm.3814 · Cited by 281
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268
“Since hepcidin arises as a key iron-regulated gene due to its function as a sensor for systemic iron availability, several strategies are envisioned to manipulate its expression [81].”
BackgroundHepcidin in Human Iron Disorders: Diagnostic Implications
Kroot, J. J., Tjalsma, H., Fleming, R. E., & Swinkels, D. W. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2009.140053 · Cited by 246
Preza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., Sharma, S., Waring, A., Ganz, T., & Nemeth, E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57693 · Cited by 234
“Although the mechanism is still not understood, transgenic expression of hepcidin in a mouse model of β-thalassemia intermedia increased hemoglobin and decreased extramedullary erythropoiesis (37).”
BackgroundSelf-citationMacrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia
Ramos, P., Casu, C., Gardenghi, S., Breda, L., Crielaard, B. J., Guy, E., Marongiu, M. F., Gupta, R., Levine, R. L., Abdel-Wahab, O., et al. (2013) · Nature Medicine · doi:10.1038/nm.3126 · Cited by 227
Self-citationReducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice
Guo, S., Casu, C., Gardenghi, S., Booten, S., Aghajan, M., Peralta, R., Watt, A., Freier, S., Monia, B. P., & Rivella, S. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66969 · Cited by 222
“Improvement in erythropoiesis could then be associated with decreased formation of insoluble globins ( α chain/heme aggregates), thereby reducing their potential toxicity when adhering to rbc membranes and producing ROS (29).”
InfluentialSelf-citationAnderson, E. R., & Shah, Y. M. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120016 · Cited by 219
Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis
Ramos, E., Ruchala, P., Goodnough, J. B., Kautz, L., Preza, G. C., Nemeth, E., & Ganz, T. (2012) · Blood · doi:10.1182/blood-2012-07-440743 · Cited by 213
Self-citationIron and Reactive Oxygen Species: Friends or Foes of Cancer Cells?
Bystrom, L. M., Guzman, M. L., & Rivella, S. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5014 · Cited by 212
“Moreover, chronic low levels of hepcidin are associated with excessive iron absorption and iron over-load (14).”
Self-citationZhao, N., Zhang, A.-S., & Enns, C. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67225 · Cited by 209
“A mouse model of β -thalassemia intermedia ( th3/+ ) has a similar phenotype (74, 75).”
Schmidt, P. J., Toudjarska, I., Sendamarai, A. K., Racie, T., Milstein, S., Bettencourt, B. R., Hettinger, J., Bumcrot, D., & Fleming, M. D. (2013) · Blood · doi:10.1182/blood-2012-09-453977 · Cited by 204
Ginzburg, Y., & Rivella, S. (2011) · Blood · doi:10.1182/blood-2011-03-283614 · Cited by 201
Self-citationHypoxia-inducible factors link iron homeostasis and erythropoiesis
Shah, Y. M., & Xie, L. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.031 · Cited by 187
Physiology and pathophysiology of iron in hemoglobin-associated diseases
Coates, T. D. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.03.039 · Cited by 181
Musallam, K. M., Cappellini, M. D., Wood, J. C., Motta, I., Graziadei, G., Tamim, H., & Taher, A. T. (2011) · Haematologica · doi:10.3324/haematol.2011.047852 · Cited by 177
“Recent evidence suggests that managing iron overload with iron chelators or more novel therapeutics could improve the efficiency of erythropoiesis and the survival of the resulting reticulocytes and erythrocytes.(39-42) Thus, iron overload may aggravate ineffective erythropoiesis and the secondary release into the cir…”
The Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders
Ganz, T., & Nemeth, E. (2011) · Hematology · doi:10.1182/asheducation-2011.1.538 · Cited by 172
Self-citationNew insights into iron regulation and erythropoiesis
Kim, A., & Nemeth, E. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000132 · Cited by 171
Self-citationDeletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia
Nai, A., Pagani, A., Mandelli, G., Lidonnici, M. R., Silvestri, L., Ferrari, G., & Camaschella, C. (2012) · Blood · doi:10.1182/blood-2012-01-401885 · Cited by 161
Hepcidin-ferroportin axis in health and disease
Ginzburg, Y. Z. (2019) · Vitamins and hormones · doi:10.1016/bs.vh.2019.01.002 · Cited by 186
“Studies in mouse models of HH and β-thalassemia syndromes demonstrate that hepcidin overexpression prevents iron overload and improves erythropoiesis, respectively (Gardenghi et al., 2010; Nicolas et al., 2003).”
BackgroundSelf-citationIron Metabolism: Interactions with Normal and Disordered Erythropoiesis
Ganz, T., & Nemeth, E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011668 · Cited by 152
“…of plasma iron in this condition may further unbalance heme and globin synthesis and worsen ineffective erythropoeisis, and conversely, that restricting the iron supply through the administration of apotransferrin or hepcidin may improve erythropoiesis (Gardenghi et al. 2010a,b; Li et al. 2010).”
BackgroundSelf-citationCappellini, M. D., Porter, J. B., Viprakasit, V., & Taher, A. T. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.001 · Cited by 182
“Moderate overexpression of hepcidin in a mouse model of betathalassaemia improved ineffective erythropoiesis, increased haemoglobin levels, reversed splenomegaly, and limited iron overload [138].”
BackgroundMinihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676742 · Cited by 148
“Discussion In b-thalassemia and anemia, increased EPO levels and expanded but ineffective erythropoiesis result in lowered hepcidin levels, increased intestinal iron absorption, and TSAT.(3,6,8,21,27) In turn, excess iron contributes to the development and worsening of ineffective erythropoiesis and reduced erythrobla…”
InfluentialSelf-citationCardiac Involvement in Hemochromatosis
Gulati, V., Harikrishnan, P., Palaniswamy, C., Aronow, W. S., Jain, D., & Frishman, W. H. (2013) · Cardiology in Review · doi:10.1097/crd.0b013e3182a67805 · Cited by 159
“Hepcidin analogs have shown to decrease iron overload and excess iron-induced tissue toxicity in mouse models.(176,177) Smaller hepcidin-like peptides called minihepcidins have also shown to reduce heart iron level in hepcidin knock-out mice.”
BackgroundSuragani, R. N. V. S., Cawley, S. M., Li, R., Wallner, S., Alexander, M. J., Mulivor, A. W., Gardenghi, S., Rivella, S., Grinberg, A. V., Pearsall, R. S., et al. (2014) · Blood · doi:10.1182/blood-2013-06-511238 · Cited by 148
“In several murine models of b-thalassemia, experimental interventions intended to alter systemic iron availability have been found to improve not only iron overloading but also erythroid differentiation.(26,38-40) Significantly, these studies did not find evidence of a direct effect of their respective interventions o…”
BackgroundSelf-citationThe pathophysiology and pharmacology of hepcidin
Ruchala, P., & Nemeth, E. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.004 · Cited by 140
“Similarly, in β-thalassemia intermedia mouse models, moderate transgenic hepcidin expression decreased iron loading of the liver, diminished splenomegaly and improved anemia [44].”
BackgroundSelf-citationMolecular liaisons between erythropoiesis and iron metabolism
Kautz, L., & Nemeth, E. (2014) · Blood · doi:10.1182/blood-2014-05-516252 · Cited by 135
Self-citationHepcidin agonists as therapeutic tools
Casu, C., Nemeth, E., & Rivella, S. (2018) · Blood · doi:10.1182/blood-2017-11-737411 · Cited by 128
Self-citationPharmacological Targeting of the Hepcidin/Ferroportin Axis
Sebastiani, G., Wilkinson, N., & Pantopoulos, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00160 · Cited by 127
The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia
Rivella, S. (2012) · Blood Reviews · doi:10.1016/s0268-960x(12)70005-x · Cited by 126
Self-citationManipulation of the hepcidin pathway for therapeutic purposes
Fung, E., & Nemeth, E. (2013) · Haematologica · doi:10.3324/haematol.2013.084624 · Cited by 123
Self-citationShenoy, N. K., Vallumsetla, N., Rachmilewitz, E. A., Verma, A., & Ginzburg, Y. Z. (2014) · Blood · doi:10.1182/blood-2014-03-563221 · Cited by 143
Self-citationRivella, S. (2015) · Haematologica · doi:10.3324/haematol.2014.114827 · Cited by 123
Self-citationIron metabolism under conditions of ineffective erythropoiesis in β-thalassemia
Rivella, S. (2019) · Blood · doi:10.1182/blood-2018-07-815928 · Cited by 120
Self-citationKatsarou, A., & Pantopoulos, K. (2018) · Pharmaceuticals · doi:10.3390/ph11040127 · Cited by 112
“Moreover, the increased hepcidin expression by these manipulations led to improved erythropoiesis in Hbbth3/+ mice [55,57].”
BackgroundSaito, H. (2014) · Institutional Repositories DataBase (IRDB) · doi:10.18999/nagjms.76.3-4.235 · Cited by 160
Iron and hepcidin: a story of recycling and balance
Camaschella, C. (2013) · Hematology · doi:10.1182/asheducation-2013.1.1 · Cited by 112
Gardenghi, S., Renaud, T. M., Meloni, A., Casu, C., Crielaard, B. J., Bystrom, L. M., Greenberg-Kushnir, N., Sasu, B. J., Cooke, K. S., & Rivella, S. (2014) · Blood · doi:10.1182/blood-2013-08-521625 · Cited by 107
Self-citationIntegrated protein quality-control pathways regulate free α-globin in murine β-thalassemia
Khandros, E., Thom, C. S., D'Souza, J., & Weiss, M. J. (2012) · Blood · doi:10.1182/blood-2011-12-397729 · Cited by 107
Chapin, J. C., & Giardina, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00040-8 · Cited by 108
Self-citationIntestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia
Anderson, E. R., Taylor, M., Xue, X., Ramakrishnan, S. K., Martin, A., Xie, L., Bredell, B. X., Gardenghi, S., Rivella, S., & Shah, Y. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314197110 · Cited by 99
Self-citationOral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia
Manolova, V., Nyffenegger, N., Flace, A., Altermatt, P., Varol, A., Doucerain, C., Sundstrom, H., & Dürrenberger, F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129382 · Cited by 98
“Hbb th3/+ mice absorb excessive amounts of iron as a consequence of inadequately low hepcidin levels 226 relative to the high iron content in liver, spleen and kidney and increased ferroportin expression in the 227 duodenum (27).”
BackgroundIneffective erythropoiesis and its treatment
Cazzola, M. (2021) · Blood · doi:10.1182/blood.2021011045 · Cited by 125
Heme metabolism and erythropoiesis
Chung, J., Chen, C., & Paw, B. H. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328351c48b · Cited by 94
‘Ride on the ferrous wheel’ – The cycle of iron in macrophages in health and disease
Nairz, M., Schroll, A., Demetz, E., Tancevski, I., Theurl, I., & Weiss, G. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.09.010 · Cited by 89
Cancer cells with irons in the fire
Bystrom, L. M., & Rivella, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.04.035 · Cited by 89
Self-citationXu, Y., Alfaro-Magallanes, V. M., & Babitt, J. L. (2020) · British Journal of Haematology · doi:10.1111/bjh.17252 · Cited by 103
“Notably, hepcidin overexpression also ameliorated anaemia and reversed ineffective erythropoiesis and splenomegaly in the thalassaemic mice.(153) This is thought to be a consequence of limiting iron availability to erythroid precursors, thereby decreasing heme production, reducing insoluble hemichrome aggregates, limi…”
BackgroundSmad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice
Wang, C.-Y., Core, A. B., Canali, S., Zumbrennen-Bullough, K. B., Ozer, S., Umans, L., Zwijsen, A., & Babitt, J. L. (2017) · Blood · doi:10.1182/blood-2016-12-759423 · Cited by 86
A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome
Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5467 · Cited by 85
Self-citationβ-Thalassemia intermedia: a comprehensive overview and novel approaches
Asadov, C. D., Alimirzoyeva, Z., Mammadova, T., Aliyeva, G., Gafarova, S., & Mammadov, J. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2411-9 · Cited by 94
Schmidt, P. J., Racie, T., Westerman, M., Fitzgerald, K., Butler, J. S., & Fleming, M. D. (2015) · American Journal of Hematology · doi:10.1002/ajh.23934 · Cited by 77
The role of TMPRSS6/matriptase-2 in iron regulation and anemia
Wang, C., Meynard, D., & Lin, H. Y.-F. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00114 · Cited by 85
“However, higher hepcidin level inhibiting iron delivery to the erythroid precursors seems to play a role as evident by the similar effects achieved by overexpression of Hamp, iron restriction, and the injection of transferrin to Hbbth3/+ mice (Gardenghi et al., 2010; Li et al., 2010; Finberg, 2013).”
BackgroundDecreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice
Li, H., Choesang, T., Bao, W., Chen, H., Feola, M., Garcia-Santos, D., Li, J., Sun, S., Follenzi, A., Pham, P., et al. (2017) · Blood · doi:10.1182/blood-2016-09-742387 · Cited by 71
“Iron-deficient diet is only partially beneficial in diseases of ineffective erythropoiesis,(38) decreasing liver iron without improving hemoglobin in b-thalassemic mice.(38) Furthermore, iron chelator deferiprone-treated b-thalassemic mice exhibit decreased liver iron with no improvement in erythropoiesis.”
BackgroundSelf-citationNCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in mice
Nai, A., Lidonnici, M. R., Federico, G., Pettinato, M., Olivari, V., Carrillo, F., Crich, S. G., Ferrari, G., Camaschella, C., Silvestri, L., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.241232 · Cited by 82
“The stable or even slightly improved phenotype secondary to the loss of Ncoa4 is in line with mild iron restriction, a condition described to ameliorate the thalassemic phenotype (25-27).”
BackgroundResultCoordinate expression of heme and globin is essential for effective erythropoiesis
Doty, R. T., Phelps, S. R., Shadle, C., Sánchez-Bonilla, M., Keel, S., & Abkowitz, J. L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83054 · Cited by 73
Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait
Jones, E., Pasricha, S.-R., Allen, A., Evans, P., Fisher, C. A., Wray, K., Premawardhena, A., Bandara, D., Perera, A., Webster, C., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606491 · Cited by 68
Arezes, J., Foy, N., McHugh, K., Quinkert, D., Benard, S., Sawant, A., Frost, J. N., Armitage, A. E., Pasricha, S.-R., Lim, P. J., et al. (2020) · Blood · doi:10.1182/blood.2019003140 · Cited by 68
Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease
Liang, R. H.-S., & Ghaffari, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14194 · Cited by 74
“One potential explanation for the differing degrees of rescue between Famb132b ablation and Hamp overexpression is the supra-physiological levels of hepcidin overexpression in these experiments, which was 2- to 4-fold higher than basal hepcidin expression (Gardenghi et al, 2010).”
BackgroundInfluentialWhat can we learn from ineffective erythropoiesis in thalassemia?
Oikonomidou, P. R., & Rivella, S. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.10.001 · Cited by 79
Self-citationHepcidin and its therapeutic potential in neurodegenerative disorders
Qian, Z., & Ke, Y. (2019) · Medicinal Research Reviews · doi:10.1002/med.21631 · Cited by 65
CHEN, B., Li, G., Shen, Y., Huang, X., & Xu, Y. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2484 · Cited by 68
Gelderman, M. P., Baek, J. H., Yalamanoglu, A., Puglia, M., Vallelian, F., Burla, B., Vostal, J., Schaer, D. J., & Buehler, P. W. (2015) · Haematologica · doi:10.3324/haematol.2014.117325 · Cited by 63
Vela, D. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0008-7 · Cited by 71
“Although transfusions recuperate hepcidin expression, IE can override regulatory control of hepcidin by iron pathways (Origa et al. 2007; Gardenghi et al. 2010).”
Background2021 update on clinical trials in β‐thalassemia
Musallam, K. M., Bou‐Fakhredin, R., Cappellini, M. D., & Taher, A. T. (2021) · American Journal of Hematology · doi:10.1002/ajh.26316 · Cited by 74
“In β-thalassemia mouse models, moderate transgenic hepcidin expression decreased iron loading in the liver, and resulted in prolonged red cell life span, increased Hb levels and amelioration of splenomegaly suggesting a bidirectional relationship between ineffective erythropoiesis and iron overload.(88) Several pre-cl…”
BackgroundLipocalin-2 and iron trafficking in the tumor microenvironment
Jung, M., Mertens, C., Bauer, R., Rehwald, C., & Brüne, B. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.018 · Cited by 68
Lobe specificity of iron binding to transferrin modulates murine erythropoiesis and iron homeostasis
Parrow, N. L., Li, Y., Feola, M., Guerra, A., Casu, C., Prasad, P., Mammen, L., Ali, F., Vaicikauskas, E., Rivella, S., et al. (2019) · Blood · doi:10.1182/blood.2018893099 · Cited by 58
Self-citationIntestinal Hypoxia-inducible Factor-2α (HIF-2α) Is Critical for Efficient Erythropoiesis
Anderson, E. R., Xue, X., & Shah, Y. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.238667 · Cited by 58
Thalassemias: from gene to therapy
Simone, G. D., Quattrocchi, A., Mancini, B., di Masi, A., Nervi, C., & Ascenzi, P. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101028 · Cited by 66
Mattè, A., Falco, L. D., Iolascon, A., Mohandas, N., An, X., Siciliano, A., Lebœuf, C., Janin, A., Bruno, M., Choi, S. Y., et al. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6237 · Cited by 53
“C57B6/2J mice as WT controls, Prx2 - mice and Hbb + , as a mouse model of b-thalassemia intermedia were used in this study (13, 15, 16, 35).”
MethodSelf-citationIron overload and chelation therapy in myelodysplastic syndromes
Temraz, S. N., Santini, V., Musallam, K. M., & Taher, A. T. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.01.006 · Cited by 56
Iron dysregulation in beta-thalassemia
Leecharoenkiat, K., Lithanatudom, P., Sornjai, W., & Smith, D. R. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2016.07.035 · Cited by 59
Management of cardiac hemochromatosis
Aronow, W. S. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.68729 · Cited by 64
“Hepicidin analogs have been demonstrated to reduce iron overload and excess iron-induced tissue toxicity in mouse models [99, 101].”
BackgroundSuperinfection in malaria: Plasmodium shows its iron will
Portugal, S., Drakesmith, H., & Mota, M. M. (2011) · EMBO reports · doi:10.1038/embor.2011.213 · Cited by 50
“By contrast, high hepcidin levels lead to increased reticulendothelial iron deposition, and mice overexpressing hepcidin have relatively reduced levels of liver iron (Gardenghi et al, 2010).”
BackgroundGene therapy for hemoglobinopathies: progress and challenges
Dong, A., Rivella, S., & Breda, L. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.011 · Cited by 62
“Ineffective erythropoiesis triggers increased iron absorption by reducing the expression of hepcidin, the hormone that controls iron absorption.(6,7) Although both transfusion and iron chelation treatments have remarkably improved over the years and, thus, improved quality of life, they do not provide a definitive cur…”
BackgroundSelf-citationKhandros, E., & Kwiatkowski, J. L. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.01.003 · Cited by 61
“Increasing hepcidin expression ameliorates iron overload in a mouse model of beta thalassemia intermedia.(72) Phase I and II trials are currently ongoing for several classes of hepcidin-targeting drugs, including hepcidin mimetics (LJPC-401, La Jolla Pharmaceutical-NCT03395704(73); PTG-300, Protagonist Therapeutics),…”
BackgroundCasu, C., Chessa, R., Liu, A., Gupta, R., Drakesmith, H., Fleming, R., Ginzburg, Y. Z., MacDonald, B., & Rivella, S. (2020) · Haematologica · doi:10.3324/haematol.2018.212589 · Cited by 50
“vival of erythroid progenitors as well as the lifespan of enucleated red blood cells (RBC).(1-6)”
BackgroundSelf-citationIron overload in β-thalassemia intermedia: an emerging concern
Musallam, K. M., Cappellini, M. D., & Taher, A. T. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32835f5a5c · Cited by 50
“Studies on mouse models mimicking human thalassemia intermedia (exhibiting nontransfusion dependent anemia, aberrant erythrocyte morphology, hepatosplenomegaly, and iron overload) not only suggested a potential role for hepcidin and transferrin therapy to decrease iron overload but also showed beneficial effects on in…”
BackgroundUnderstanding Metal Dynamics Between Cancer Cells and Macrophages: Competition or Synergism?
Serra, M., Columbano, A., Ammarah, U., Mazzone, M., & Menga, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00646 · Cited by 55
Late stage erythroid precursor production is impaired in mice with chronic inflammation
Prince, O. D., Langdon, J. M., Layman, A. J., Prince, I. C., Sabogal, M., Mak, H. H., Berger, A. E., Cheadle, C., Chrest, F. J., Yu, Q., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.053397 · Cited by 48
“We used antibodies to assess stage-specific markers of erythropoiesis to analyze erythroid precursor maturation by flow cytometry, resolving erythroid precursors by Ter119 and CD44 staining as previously described.(3,4) We found significant numbers of erythroid precursors in spleens of mice with sterile abscesses (Onl…”
MethodSelf-citationThe Role of Catalytic Iron in Acute Kidney Injury
Shah, S. V., Rajapurkar, M. M., & Baliga, R. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08340811 · Cited by 50
Tantawy, A. A. G., Adly, A. A. M., Ismail, E. A. R., & Habeeb, N. M. M. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12108 · Cited by 47
“Moreover, iron chelators could improve the efficiency of erythropoiesis and the survival of the resulting reticulocytes and erythrocytes, thus decreases MPs levels (67, 68).”
BackgroundHaase‐Fielitz, A., Mertens, P. R., Plaß, M., Kuppe, H., Hetzer, R., Westerman, M. E., Ostland, V. E., Prowle, J. R., Bellomo, R., & Haase, M. (2011) · Critical Care · doi:10.1186/cc10339 · Cited by 50
“A multitude of studies have investigated hepcidin in a number of nonrenal diseases, for example, as a marker of anemia [26-28], but also in CKD [29,30].”
BackgroundDas, N., Xie, L., Ramakrishnan, S. K., Campbell, A., Rivella, S., & Shah, Y. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.c115.681643 · Cited by 46
Self-citationModulation of Hepcidin as Therapy for Primary and Secondary Iron Overload Disorders
Schmidt, P. J., & Fleming, M. D. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.11.004 · Cited by 42
“For example, dietary iron restriction has similar effects on anemia and ineffective erythropoiesis in the Hbb mouse model.(55) Furthermore, RBC parameters in both of these models change in a manner that would suggest more severe iron deficiency: both Tf-treated Hbb and iron-deficient Hbb”
BackgroundPetzer, V., Tymoszuk, P., Aßhoff, M., Carvalho, J. A., Papworth, J., Deantonio, C., Bayliss, L., Wake, M., Seifert, M., Brigo, N., et al. (2020) · Blood · doi:10.1182/blood.2019004653 · Cited by 51
Contemporary approaches to treatment of beta-thalassemia intermedia
Taher, A. T., Musallam, K. M., Karimi, M., & Cappellini, M. D. (2012) · Blood Reviews · doi:10.1016/s0268-960x(12)70008-5 · Cited by 43
Controversies on the Consequences of Iron Overload and Chelation in MDS
Vinchi, F., Hell, S., & Platzbecker, U. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000357 · Cited by 42
Bridle, A. R., Koop, B. F., & Nowak, B. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040841 · Cited by 40
Metadata
- Authors
- Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., Muirhead, K., Rao, N., Roy, C. N., Andrews, N. C., Nemeth, E., Follenzi, A., An, X., Mohandas, N., Ginzburg, Y., Rachmilewitz, E. A., Giardina, P. J., Grady, R. W., & Rivella, S.
- Affiliations
- Weill Cornell Medicine (US)
- Johns Hopkins University (US)
- Duke University (US)
- University of California, Los Angeles (US)
- Albert Einstein College of Medicine (US)
- New York Blood Center (US)
- Wolfson Medical Center (IL)
- Corresponding author
- Rivella, Stefano
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-12-01
- Volume
- 120
- Issue
- 12
- Pages
- 4466-4477
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2993583
- OpenAlex
- W2163438420
- Cited by
- 220
- References
- 31
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 7 · 2023: 9 · 2022: 6 · 2021: 12 · 2020: 9 · 2019: 19 · 2018: 14 · 2017: 17 · 2016: 13 · 2015: 19 · 2014: 26 · 2013: 21 · 2012: 21
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- Cooley's Anemia Foundation
- American Portuguese Biomedical Research Fund
- National Institutes of Health (10021)
- College of Veterinary Medicine, Cornell University
- Weill Cornell Medical College
- Fundação para a Ciência e a Tecnologia (SFRH/BD/24813/2005)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK055463, KO1DK065635, R01DK090554, R01DK082717, R01DK55463, K01DK065635)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- hepcidin, beta-thalassemia, iron overload, iron absorption, ferroportin, anemia, ineffective erythropoiesis, splenomegaly, reactive oxygen species, red blood cell lifespan, iron metabolism
- MeSH terms
- Animals, Base Sequence, Disease Models, Animal, Erythropoiesis, Humans, Iron, Mice, Inbred C57BL, Mice, Mutant Strains, Mice, Transgenic, Recombinant Proteins, Gene Expression, beta-Thalassemia, DNA Primers, Iron Overload, Iron, Dietary, Antimicrobial Cationic Peptides, Mice, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.